神经科学学会——第39届年会。第二部分——神经退行性疾病和其他中枢神经系统疾病的新型疗法。

Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.

作者信息

Al-Shamahi Asma, Kirkham Konrad, Hookes Livia

机构信息

Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK.

出版信息

IDrugs. 2009 Dec;12(12):734-7.

PMID:19943211

Abstract

The 39th Annual Meeting of the Society for Neuroscience (SFN), held in Chicago, included topics covering new therapeutic developments in the field of neuroscience. This conference report highlights selected presentations on novel neuroprotective and antiparkinsonian agents, and compounds in development for the treatment of dementia, schizophrenia, depression, obesity and spinal muscular atrophy. Investigational drugs discussed include velusetrag and TD-8954 (both from Theravance Inc), SEP-228791 and SEP-226330 (both from Sepracor Inc), ADL-5510 (Adolor Corp), PF-217830 (Pfizer Inc), KB-099520 (Karo Bio AB), tesofensine (NeuroSearch A/S) and TRP6-01 (Theraptosis).

摘要

在芝加哥举行的第39届神经科学学会（SFN）年会涵盖了神经科学领域新治疗进展的诸多主题。本会议报告重点介绍了有关新型神经保护剂和抗帕金森病药物，以及正在研发用于治疗痴呆、精神分裂症、抑郁症、肥胖症和脊髓性肌萎缩症的化合物的部分演讲内容。讨论的研究性药物包括维卢司曲和TD - 8954（均来自Theravance公司）、SEP - 228791和SEP - 226330（均来自Sepracor公司）、ADL - 5510（Adolor公司）、PF - 217830（辉瑞公司）、KB - 099520（卡罗生物公司）、替索芬辛（NeuroSearch公司）和TRP6 - 01（Theraptosis公司）。